Literature DB >> 26470999

Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide Survey.

Woon Geon Shin1, Sang Woo Lee2, Gwang Ho Baik1, Kyu Chan Huh3, Sang In Lee4, Jun-Won Chung5, Woon Tae Jung6, Moo In Park7, Hye-Kyung Jung8, Heung Up Kim9, Jeong Hwan Kim10, Sang Young Seol11, Soon Man Yoon12, Seong Woo Jeon13, Su Jin Hong14, Gwang Ha Kim15, Dong Ho Lee16, Hyun Soo Kim17, Suck Chei Choi18, Hee Mo Kang19, Joongyub Lee20,21, Jae Gyu Kim22, Jae J Kim23.   

Abstract

BACKGROUND: The efficacy of proton-pump inhibitor-amoxicillin-clarithromycin therapy for H. pylori eradication has decreased over time.
OBJECTIVE: We assessed the trend of H. pylori eradication rates over the last 10 years and the relationship between the eradication rates and the amount of macrolide antibiotic use in a country with a high prevalence of H. pylori infection.
METHODS: This vast nationwide multicenter study was conducted with 34,139 adults treated for H. pylori infection from January 2001 to December 2010. The defined daily dose per km(2) (DSD) of macrolide antibiotics was calculated (n = 141,019) using the Health Insurance Review & Assessment data base from 2008 to 2010 in the two cities which had the lowest (Jeju city) or highest (Chuncheon city) eradication rate.
RESULTS: The eradication rates of proton-pump inhibitor-amoxicillin-clarithromycin therapy ranged 84.9-87.5% from 2001 to 2007, and those of 2008 to 2010 ranged 80.0-81.4% with a decreasing trend (p < 0.0001). The decreasing trend of eradication rates for the overall first-line therapy was observed only in three of the seven geographic areas in Korea (p < 0.0001). The DSD of macrolide antibiotics was significantly higher in Jeju than Cheunchon city (0.85 vs 0.52, p < 0.0001).
CONCLUSIONS: H. pylori eradication rates with clarithromycin-containing triple therapy in Korea showed a decreasing trend over the past 10 years, although the trend varied among geographic areas. This difference may be associated with the amount of macrolide antibiotic use.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  Helicobacter pylori; antibiotics; treatment failure; trends

Mesh:

Substances:

Year:  2015        PMID: 26470999     DOI: 10.1111/hel.12279

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  18 in total

1.  Early Attempts to Eradicate Helicobacter pylori after Endoscopic Resection of Gastric Neoplasm Significantly Improve Eradication Success Rates.

Authors:  Cheal Wung Huh; Young Hoon Youn; Da Hyun Jung; Jae Jun Park; Jie-Hyun Kim; Hyojin Park
Journal:  PLoS One       Date:  2016-09-02       Impact factor: 3.240

2.  Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication.

Authors:  Ji Young Chang; Ki-Nam Shim; Chung Hyun Tae; Ko Eun Lee; Jihyun Lee; Kang Hoon Lee; Chang Mo Moon; Seong-Eun Kim; Hye-Kyung Jung; Sung-Ae Jung
Journal:  BMC Gastroenterol       Date:  2017-01-21       Impact factor: 3.067

3.  Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes.

Authors:  Sung Eun Kim; Moo In Park; Seun Ja Park; Won Moon; Jae Hyun Kim; Kyoungwon Jung; Hae Koo Kim; Young Dal Lee
Journal:  World J Gastroenterol       Date:  2017-02-14       Impact factor: 5.742

4.  Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease.

Authors:  Joo Hyun Lim; Sang Gyun Kim; Ji Hyun Song; Jae Jin Hwang; Dong Ho Lee; Jae Pil Han; Su Jin Hong; Ji Hyun Kim; Seong Woo Jeon; Gwang Ha Kim; Ki-Nam Shim; Woon Geon Shin; Tae Ho Kim; Sun Moon Kim; Il-Kwon Chung; Hyun-Soo Kim; Heung Up Kim; Joongyub Lee; Jae Gyu Kim
Journal:  Gut Liver       Date:  2017-03-15       Impact factor: 4.519

5.  Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial.

Authors:  Hyuk Lee; Beom Jin Kim; Sang Gyun Kim; Jin Il Kim; Il Ju Choi; Yong Chan Lee; Jae G Kim; Jae J Kim
Journal:  Trials       Date:  2017-11-17       Impact factor: 2.279

6.  Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial.

Authors:  Hyun Lim; Chang Seok Bang; Woon Geon Shin; Jae Ho Choi; Jae Seung Soh; Ho Suk Kang; Young Joo Yang; Ji Taek Hong; Suk Pyo Shin; Ki Tae Suk; Jae Jun Lee; Gwang Ho Baik; Dong Joon Kim
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

7.  Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020.

Authors:  Hye-Kyung Jung; Seung Joo Kang; Yong Chan Lee; Hyo-Joon Yang; Seon-Young Park; Cheol Min Shin; Sung Eun Kim; Hyun Chul Lim; Jie-Hyun Kim; Su Youn Nam; Woon Geon Shin; Jae Myung Park; Il Ju Choi; Jae Gyu Kim; Miyoung Choi
Journal:  Korean J Intern Med       Date:  2021-06-08       Impact factor: 2.884

Review 8.  Management of immune thrombocytopenia: Korean experts recommendation in 2017.

Authors:  Jun Ho Jang; Ji Yoon Kim; Yeung-Chul Mun; Soo-Mee Bang; Yeon Jung Lim; Dong-Yeop Shin; Young Bae Choi; Ho-Young Yhim; Jong Wook Lee; Hoon Kook
Journal:  Blood Res       Date:  2017-12-26

9.  Clinical Outcomes of Standard Triple Therapy Plus Probiotics or Concomitant Therapy for Helicobacter pylori Infection.

Authors:  Jae Hyun Jung; In Kuk Cho; Chang Hee Lee; Gwan Gyu Song; Ji Hyun Lim
Journal:  Gut Liver       Date:  2018-03-15       Impact factor: 4.519

10.  An Economic Modeling Study of Helicobacter pylori Eradication: Comparison of Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction and Empirical Treatment.

Authors:  Tae-Geun Gweon; Joon Sung Kim; Byung-Wook Kim
Journal:  Gut Liver       Date:  2018-11-15       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.